CHOI, DONGHOON,崔东勋,崔東勛,EUN, CHANGYONG,殷畅容,殷暢容,JEONG, SEONG HOON,郑圣勋,鄭聖勛,LIM, JUN YEUL,林埈热,林埈熱
申请号：
TW105136023
公开号：
TW201722461A
申请日:
2016.11.04
申请国别(地区):
TW
年份:
2017
代理人:
摘要：
Provided is a pharmaceutical formulation comprising a modified IL-7 protein. More particularly, it comprises (a) a modified IL-7 fusion protein (b) a basal buffer with a concentration of 10 to 50 mM (c) a sugar with a concentration of 2.5 to 5w/v% and (d) a surfactant with a concentration of 0.05 to 6w/v%.Such pharmaceutical formulation of a modified IL-7 fusion protein does not show aggregates formation, but shows protective effects on proteins under stress conditions such as oxidation or agitation, and thus can effectively be used for the treatment of a patient.在此提供的是一種包含經修飾之IL-7蛋白的藥學調配物。更具體地說,其包含(a)經修飾之IL-7融合蛋白;(b)濃度為10至50mM之基礎緩衝液;(c)濃度為2.5至5w/v%之糖;以及(d)濃度為0.05至6w/v%之界面活性劑。此經修飾之IL-7融合蛋白的藥學調配物在諸如氧化或攪拌之應力條件下,不會顯示出凝集的形成,而是會在蛋白上顯示出保護作用,因此可有效地用於治療病人。
